Myocardial blood flow and infarct size after CD133+ cell injection in large myocardial infarction with good recanalization and poor reperfusion: results from a randomized controlled trial
Authors:
- Alessandro ColomboACAlessandro Colombo
- Massimo CastellaniMCMassimo Castellani
- Emanuela PiccalugaEPEmanuela Piccaluga
- Enrico PusineriEPEnrico Pusineri
- Simone PalatresiSPSimone Palatresi
- Virgilio LongariVLVirgilio Longari
- Cristina CanziCCCristina Canzi
- Elisabetta SacchiESElisabetta Sacchi
- Edoardo RossiEREdoardo Rossi
- Roberto RechRRRoberto Rech
- Paolo GerundiniPGPaolo Gerundini
- Maurizio VieccaMVMaurizio Viecca
- 1 April 2011
- journal article
- research article
- Published by Wolters Kluwer Health in Journal of Cardiovascular Medicine
- Vol. 12 (4) , 239-248
Abstract
Large acute ST-elevation myocardial infarction (STEMI) sometimes leaves extensive ischemic damage despite timely and successful primary angioplasty. This clinical picture of good recanalization with incomplete reperfusion represents a good model to assess the reparative potential of locally administered cell therapy. Thus, we conducted a randomized controlled trial aimed at evaluating the effect of intracoronary administration of CD133 stem cells on myocardial blood flow and function in this setting. Fifteen patients with large anterior STEMI, myocardial blush grade 0-1 and more than 50% ST-elevation recovery after optimal coronary recanalization (TIMI 3 flow) with stenting were randomly assigned to receive CD133 cells from either bone marrow (group A) or peripheral blood (group B), or to stay on drug therapy alone (group C). The cells were intracoronary injected within 10-14 days of STEMI. Infarct-related myocardial blood flow (MBF) was evaluated by NH positron emission tomography 2-5 days before cell administration and after 1 year. MBF increased in the infarct area from 0.419 (0.390-0.623) to 0.544 (0.371-0.729) ml/min per g in group A, decreased from 0.547 (0.505-0.683) to 0.295 (0.237-0.472) ml/min per g in group B and only slightly changed from 0.554 (0.413-0.662) to 0.491 (0.453-0.717) ml/min per g in group C (A vs. C: P = 0.023; B vs. C: P = 0.066). Left ventricular volume tended to increase more in groups B and C than in group A, ejection fraction and wall motion score index remained stable in the three groups. These findings support the hypothesis that intracoronary administration of bone marrow-derived, but not peripheral blood-derived CD133 cells 10-14 days after STEMI may improve long-term perfusion.Keywords
This publication has 37 references indexed in Scilit:
- Autologous bone marrow stem cells to treat acute myocardial infarction: a systematic reviewEuropean Heart Journal, 2008
- Intracoronary infusion of autologous mononuclear cells from bone marrow or granulocyte colony-stimulating factor-mobilized apheresis product may not improve remodelling, contractile function, perfusion, or infarct size in a swine model of large myocardial infarctionEuropean Heart Journal, 2008
- Evidence that intracoronary-injected CD133+ peripheral blood progenitor cells home to the myocardium in chronic postinfarction heart failureExperimental Hematology, 2007
- Absence of a relationship between immunophenotypic and colony enumeration analysis of endothelial progenitor cells in clinical haematopoietic cell sourcesJournal of Translational Medicine, 2007
- Human CD34+AC133+VEGFR-2+ cells are not endothelial progenitor cells but distinct, primitive hematopoietic progenitorsExperimental Hematology, 2007
- The Failing Heart — An Engine Out of FuelNew England Journal of Medicine, 2007
- Intracoronary infusion of the mobilized peripheral blood stem cell by G-CSF is better than mobilization alone by G-CSF for improvement of cardiac function and remodeling: 2-Year follow-up results of the Myocardial Regeneration and Angiogenesis in Myocardial Infarction with G-CSF and Intra-Coronary Stem Cell Infusion (MAGIC Cell) 1 trialAmerican Heart Journal, 2007
- In vitro and in vivo effects of bone marrow stem cells on cardiac structure and functionJournal of Molecular and Cellular Cardiology, 2007
- Cytokines produced by bone marrow cells can contribute to functional improvement of the infarcted heart by protecting cardiomyocytes from ischemic injuryAmerican Journal of Physiology-Heart and Circulatory Physiology, 2006
- Intramyocardial delivery of human CD133+ cells in a SCID mouse cryoinjury model: Bone marrow vs. cord blood-derived cells☆Cardiovascular Research, 2006